When former FDA commissioner Scott Gottlieb, M.D., resigned back in March, he said he wanted to spend more time with his family.
Since then, Gottlieb has nabbed a partnership at a VC firm and a think tank fellowship. And now, less than three months since his last day regulating pharma, Gottlieb has joined Pfizer, one of the biggest companies in the business.
Gottlieb snagged a spot on Pfizer’s board of directors, the drug giant said Thursday. He’ll also serve on the board’s regulatory and compliance committee and its science and technology committee.
The announcement comes 85 days after Gottlieb left the FDA on April 5 to spend more time with his family. In his resignation letter to colleagues, Gottlieb wrote that “there’s nothing that could pull me away from this role other than the challenge of being apart from my family for these past two years and missing my wife and two young children.”
Since leaving the FDA, Gottlieb joined New Enterprise Associates as a special partner. He’s also a resident fellow at the American Enterprise Institute, according to Pfizer.
While the new roles surely aren’t as demanding as FDA commissioner, Gottlieb’s quick jump back to industry is sure to raise eyebrows. He was arguably among the most popular Trump appointments as agency chief, but his quick leap back to industry conflicts with President Donald Trump’s campaign pledge to “drain the swamp” and fight corporate influence in Washington.
Pfizer Executive Chairman Ian Read said Gottlieb’s “expertise in health care, public policy and the industry will be an asset to our company and enable our shareholders to continue to benefit from a board representing a balance of experience, competencies and perspectives.”
By Eric Sagonowsky
Source: Fierce Pharma
Hybrid closed-loop systems rely on an algorithm to first analyze real-time blood sugar readings from a continuous glucose monitor, then use the results to adjust an insulin pump’s output as needed throughout the day. In this case, the algorithm was developed by Diabeloop, the CGM is a Dexcom G6 sensor, and the insulin pump comes from ViCentra.
Boehringer Ingelheim has acquired bacterial cancer therapy company T3 Pharmaceuticals in a deal that could be worth up to 450 million Swiss francs ($508 million). The addition of Allschwil, Switzerland-based T3 will “significantly expand” the German drugmaker’s immuno-oncology pipeline and aligns with some of the company’s existing R&D programs.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. The acquisition, announced in August, further differentiates its value proposition to support a broader client base across the whole oligonucleotide development continuum, from research to commercialization, EuroAPI said.
